ThromboGenics in eye drug deal with Novartis unit Alcon
19.03.2012 - Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S.
ThromboGenics said it will concentrate on commercialising ocriplasmin in the U.S., where it plans to build its commercial and medical organisation to support the anticipated launch of the eye drug within the next 12 months. The truncated form of the human serine protease plasmin is under review in Europe for the indication symptomatic vitreomacular adhesion. ThromboGenics will receive an up-front payment of €75m and is eligible for a further €90m in potential near-term milestone payments. Additional milestones would bring the potential total of up-fronts and milestones to €375m according to ThromboGenics. The Belgian company will have a "strategic and focused operational role" in the commercialisation of the product in the five largest European markets. The partners will also co-develop ocriplasmin in additional indications, with both companies responsible for development costs. Details were not disclosed. Ocriplasmin is Thrombogenics' lead product. It represents an injectable recombinant microplasmin, a truncated form of the natural human protein plasmin. The drug has successfully completed two Phase III clinical trials for the pharmacological treatment of the eye disease symptomatic vitreomacular adhesion.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.